The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Efficacy of Elranatamab in Combination With Carfilzomib and Dexamethasone in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Michael H Tomasson, Eli Gabayan, Syed Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou, Ola Landgren
Elranatamab + Maplirpacept (TTI-622 | PF-07901801) | December 9, 2024 | ASH 2024
C1071020 | NCT05675449
Poster
Pharmacokinetic Analyses and Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Lincha V, Hadigol M, Wang Y, Chan C, Tibbetts F, Kuttschreuter L, Wang D
Maplirpacept (TTI-622 | PF-07901801) | September 8, 2024 | ACCP 2024
C4971001 | NCT03530683